Inhaled corticosteroid therapy in Asthma and Osteoporosis

Abstract

osteoporosis, concluded that ICS was safe, not affecting BMD. 3 On the other hand, Monadi M et al., reported a significant decrease in BMD in asthmatic patients under 50years old, but not in patients over 50years when treated ICS. 4 The authors proposed to conduct a prospective study with BMD assessment in asthmatic patients treated with ICS for at least 5years. Exclusion criteria were defined: postmenopausal women, men 65years or older, patients undergoing immunosuppressive therapies, patients with immunodeficiency disorders or cancer. The study included patients seen at the Severe Asthma and Allergology outpatient clinic of Centro Hospital Universitário Coimbra (CHUC), between July and October 2018. The selected patients underwent DEXA at the Nuclear Medicine department of CHUC.Patient's demographics are referred in Table 1. Of the 14 patients included, 7 are men under 50years of age or women premenopausal